Efficacy of a physical activity regimen on visual outcomes among persons newly

- diagnosed with abnormal glucose tolerance: Study protocol for a pilot randomized controlled trial.
- Ebenezer Oduro Antiri^{1,2¶*}, Thomas Hormenu^{1,2¶}, Edward Wilson Ansah^{1¶}, Stephen Ocansey^{3¶},
- Rudolf Aaron Arthur^{2,4}, Eric Awlime-Ableh^{1,2}, Iddrisu Salifu², Benjamin Nyane^{2,4}, Augustine
- Mac-Hubert Gabla^{1,2¶}, Juliet Elikem Paku^{1,2¶}
- ¹Department of Health, Physical Education and Recreation, University of Cape Coast, Cape Coast, Ghana
- ²Cardiometabolic Epidemiology Research Laboratory, Department of Health, Physical Education
- and Recreation, University of Cape Coast, Cape Coast, Ghana
- ³Department of Optometry and Vision Science, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana
- ⁴Directorate of University Health Services, University of Cape Coast, Cape Coast, Ghana

- * Corresponding author
- Email: oduro.antiri@gmail.com (EOA)

- [¶]These authors contributed equally to this work.
- **Funding Statement**
- This study is expected to be carried out without external funding

32 Abstract

Background: Abnormal Glucose Tolerance (AGT), which encompasses diabetes and prediabetes, is a growing health problem globally. It is affecting millions and predisposing such patients to several complications, including ocular complications. Physical activity has been found to improve glycemic levels, but the specific effect on visual outcomes in a newly diagnosed African population with AGT is yet to be explored fully. This pilot randomized controlled trial seeks to evaluate the efficacy of a physical activity intervention among newly diagnosed persons with AGT in Cape Coast, Ghana.

Methods: An ostensibly healthy population will be screened for AGT. Persons newly 40 diagnosed with AGT will be recruited into the randomized controlled trial. About 50 newly 41 42 diagnosed participants with AGT will undergo a 12-week moderate-to-vigorous physical activity (MVPA) intervention, specifically exercises that burn more than 3.0 metabolic 43 equivalents (METs), to ascertain its effect on their visual acuity, contrast sensitivity, central 44 45 visual field and diabetic retinopathy status. The participants will be randomized into a physical activity intervention group and a control group. Assessments will be done at 46 baseline, and treatment outcomes will be done on the last day of the intervention for each 47 48 participant.

Discussion: Physical activity is a proven lifestyle intervention that reduces glycemic levels in people with AGT. Unfortunately, many persons are unaware of their high level of glucose tolerance, which is associated with the deterioration of vision. This study intends to investigate and present findings on the advantages of physical activity interventions on visual outcomes among people with AGT. The study holds promise in informing evidencebased interventions for persons with AGT in poor economies.

55 **Clinical trial registration**

This trial has been registered with the Pan African Clinical Trails Registry with the identifier:
 PACTR202401462338744.

58

Key words: Abnormal Glucose Tolerance, Physical Activity Intervention, Visual Outcomes, Randomized Controlled Trial, Ghana

61

62

64 Background

Abnormal Glucose Tolerance (AGT), with all its negative health implication, is gradually 65 becoming a regularized phenomenon with which society must contend. Instances of 66 Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG), and/or diabetes mellitus 67 all identify as situations of AGT. The number of adults who suffer from only diabetes mellitus 68 is estimated to experience a surge from 537 million adults to 783 million by 2045 (1). 69 70 Additionally, there are also an estimated 541 million adults who have Impaired Glucose Tolerance (IGT) or prediabetes, making them highly susceptible to developing diabetes and 71 72 its complications (1–3). Even without consideration of all other instances of Abnormal Glucose Tolerance (AGT), the estimated rate of growth of adults with diabetes mellitus is 73 quite alarming. 74

In Ghana, the estimated prevalence of diabetes mellitus has been pegged at a high rate of 75 76 6.5% (4). As typical on the global scene, Type 2 Diabetes Mellitus (T2DM) is the most common in Ghana. It is important to acknowledge that instances of Abnormal Glucose 77 78 Tolerance (AGT) such as overt diabetes have extensive precarious effects on an individual's 79 health system, such as one's ocular health (5). Diabetic Retinopathy (DR), which is the one of most common microvascular complications of T2DM (6), has the tendency to cause total 80 blindness if not managed properly (7). According to the literature (7), almost 60% of T2DM 81 patients are found to have some form of diabetic retinopathy. Unfortunately, diabetic 82 retinopathy has been a leading cause of adult-onset blindness in the past decade (8). 83

Type 2 Diabetes Mellitus (T2DM) is heavily influenced by both modifiable and partially adjustable risk factors, making it the most modifiable kind of diabetes (1,9). For example,

previous studies have demonstrated that lifestyle changes, including a healthier diet and 86 more physical activity significantly lower the risk of developing complications from T2DM 87 (10–12). They also show that the vice versa is also possible where there can be complex 88 89 complications from T2DM. It has been observed that there are numerous health advantages of physical activity such as improving glucose control, lipid profiling, and cardiovascular 90 health, which help manage instances of AGT (13). Such demonstrations and observations 91 suggest that in the instance of Diabetic Retinopathy (DR), for example, physical activity 92 would have a direct impact on its management. 93

94 In fact, there have been studies that have investigated the associations between hyperglycemia (as associated with AGT) and visual functions, with these studies showing an 95 observable reduction in visual functions due to hyperglycemia (14–20). Thus, these studies 96 recommended lifestyle interventions like dietary changes and increased physical activity to 97 improve visual outcomes. Further clinical trials also reported some positive change in visual 98 functioning as a result of physical activity participation (21,22). However, many of the 99 100 studies, as with the clinical trials, did not include an African population and persons with the prediabetes condition (5,21-23). Many of those studies rather focused on people diagnosed 101 with diabetes who are likely to be on other prescribed interventions (5,21-23). Additionally, 102 103 they assessed physical activity levels subjectively, by relying on patients' self-reported data (21,22). 104

There is, therefore, the need for additional investigations into the related effects of physical activity and AGT, established through an objectively self-monitored physical activity regimen on visual outcomes in newly diagnosed persons with AGT from Africa.

Understanding the direct impact of physical activity on AGT-related visual outcomes will 108 enable the development of a more concise, evidence-based interventions for patients with 109 AGT related ocular health issues. In that regard, the present study seeks interventions that 110 111 are cost effective, person-specific, and target-driven. It has been suggested that cost-effective interventions are sustainable and can easily lead to actual lifestyle modification because they 112 can be done without significant financial burden (24,25). Studies also show that such 113 interventions need to be person-specific to be successful (26). For instance, persons with 114 AGT may have varying characteristics, and tailoring physical activity interventions to their 115 unique characteristics and needs is crucial for enhancing its adherence and effectiveness 116 (27,28). Providing specific targets for a physical activity intervention is also another 117 important factor, as it motivates participants and helps track their progress in adhering to 118 the intervention (29). 119

In 2024, the International Diabetes Federation (IDF) and the International Agency for the 120 Prevention of Blindness (IAPB) published a policy brief to help the development and 121 implementation of measures to reduce diabetic eye disease worldwide (30). This trial 122 protocol describes how the recommendations of developing contextually appropriate 123 screening and treatment interventions, as well as building capacity in monitoring and 124 125 evaluating progress of people with diabetic retinopathy can be implemented in an African population. Thus, the present study explores the effect of a cost-effective, person-specific, 126 and target-driven physical activity regimen on visual outcomes among persons newly 127 diagnosed with AGT in Cape Coast, Ghana. 128

129 **Objectives**

The main objective of this study is to evaluate the feasibility of carrying out a double-blind Randomized Controlled Trial (RCT) and to investigate the effects of a moderate-to-vigorous physical activity (MVPA) regimen on visual outcomes among persons newly diagnosed with AGT in Cape Coast. The secondary objective is to investigate whether a physical activity regimen will influence the ability of the experimental group to cope with their daily visual demands, in comparison to the control group.

136 Methods

137 Study design

This study is a 12-week pilot and feasibility study with a double-blind, randomized control 138 trial. The design will focus on the preliminary efficacy of physical activity to impact visual 139 outcomes among newly diagnosed persons with AGT. The trial is designed based on the 140 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)(31) and will 141 compare an experimental group (physical activity regimen) and an active placebo group 142 (lifestyle change education), randomized into their respective groups in a 1:1 ratio. The trial 143 design is further illustrated in Figures 1 and 2. The study protocol has been approved by the 144 145 University of Cape Coast Institutional Review Board (UCCIRB) (UCCIRB/EXT/2022/27). The 146 protocol is registered with the Pan African Clinical Trails Registry 147 (PACTR202401462338744).

148 Fig 1. SPIRIT schedule of enrolment, interventions, and assessments

149 Fig 2. Flow chart of the RCT process for the participants in the study

150 Settings and population

The study will be conducted at the Cardiometabolic Epidemiology Research Laboratory (CERL), University of Cape Coast. Recruitment will be carried out in communities in Cape Coast, Ghana. Moreover, the participants will be persons who have been newly diagnosed with AGT.

155 Eligibilty criteria

All prospective participants in this trial will be well informed about the study. The 156 participants will provide written or oral consent to participate in the trial. The inclusion 157 criteria for the trial comprise: a) Newly diagnosed persons with AGT; and b) people between 158 the ages of 25 and 70. The exclusion criteria for the trial comprise: a) Pregnant women and 159 breastfeeding mothers; b) individuals with pre-existing diabetes (either type 1 or type 2); c) 160 individuals with a BMI below 18.5 kg/m²; d) individuals with anemia; e) individuals with 161 cardiac comorbidities or signs of cardiovascular instability; and f) individuals with any other 162 contraindicated condition for moderate-intensity physical activity. 163

164 Allocation and blinding

The participants in this study will be randomized into experimental or control groups, using the software <u>www.randomizer.org</u>. This process will be done by an independent researcher who will not take part in the intervention and evaluation stages of this trial. The randomization process will be done at a 1:1 ratio, with each participant given a special number.

Since the trial is double-blinded, both researchers and participants will be masked to theentire randomization process. As required, the researcher conducting the intervention will

not take part in the evaluations while the evaluator will not know the allocations of theparticipants.

174 **Procedure**

175 There will be a preliminary screening of the population to diagnose and identify individuals with AGT suffering from visual problems in the in the communities. This screening of the 176 population in Coast to identify people eligible for the trial began in the first quarter of 2023 177 and ended in the final quarter of 2023. Individuals will be included in the clinical trial if they 178 are diagnosed with AGT, being either prediabetes or diabetes for any of the Fasting Blood 179 Glucose (FBG), Glycated Hemoglobin (HbA1c) and Oral Glucose Tolerance Test (OGTT) 180 diagnostic tests. In addition, these individuals must have visual functioning deficits, 181 including visual acuity, contrast sensitivity, and central visual field. Such individuals will 182 then be informed of the purpose of the trial and their voluntary participation in the study 183 will be solicited. Also, the Visual Disability Index of each participant will be measured using 184 the Visual Disability Questionnaire (32). Those who will agree to take part in the study will 185 then be given an informed consent form to sign (to take part in the baseline and pre-186 intervention assessments). 187

When the baseline and pre-intervention assessments have been conducted, an independent researcher will then assign the participants into either the experimental or control groups based on the 1:1 randomization using the randomization software. A researcher will be responsible for explaining the physical activity regimen to the experimental group, as well as setting up the fitness applications on their smartphones that will be used for estimating daily physical activity levels. Another researcher will also provide the necessary information to the control group for this trial. The physical activity will be a macrocycle of 12 weeks, with three mesocycles consisting of four weeks each. Participants in the experimental group will be contacted every four weeks to enquire of the possible occurrences. This feedback will inform the next decision of whether the participants should move from one mesocycle to another, based on their adherence levels and willingness to continue. After the conclusion of the last week of the intervention phase, participants will be assessed at CERL on all parameters assessed at the baseline and pre-intervention stages.

202 Assessments

The assessments for this trial will be conducted at CERL. All measures are expected to last
around 120 minutes for each participant. The measures for this trial include:

Fasting Blood Glucose (FBG): FBG will be measured after at least 8 hours of fasting using a
 glucometer. Blood samples will be taken from the participants and analyzed for blood
 glucose concentration, at mmol/L.

208 *Glycated Hemoglobin (HbA1c):* HbA1c will be measured from a blood sample that will be 209 taken from participants using the HbA1c analyzer.

Oral Glucose Tolerance Test (OGTT): The glucose tolerance of the participants will be examined through the OGTT. Each participant will drink a 75g glucose solution after fasting overnight. Baseline glucose level will be measured, after which blood samples are taken at 1 hour and 2 hours after ingesting the glucose solution. The glucose levels then will be measured and analyzed. The glucose level recorded at exactly 2 hours after ingestion will determine whether the participant can be considered normal (less than 140 mg/dL), prediabetic (140 to 199 mg/dL), or diabetic (200 mg/dL or higher) (33).

Body Mass Index: Height and weight will be measured as means to gauge participants' BMI.

217 The participants will then be classified as severely underweight (less than 16.5kg/m^2). 218 underweight (under 18.5 kg/m²), normal weight (from 18.5 to 24.9 kg/m²), overweight (25 219 220 to 29.9 kg/m²), obesity (greater than or equal to 30 kg/m²), with sub-classifications of obesity class I (30 to 34.9 kg/m²), obesity class II (35 to 39.9 kg/m²) and obesity class III 221 (greater than or equal to 40 kg/m^2) (34). 222

Visual Acuity (VA): VA will be measured using the Early Treatment Diabetic Retinopathy 223 Study (ETDRS) Chart for high contrast acuity. This chart reports VA on a log of the minimum 224 angle of resolution (logMAR). 225

Contrast Sensitivity (CS): CS will be measured using a Pelli-Robson chart under standardized 226 light conditions. This test measures the ability of the participants to discern letters at 227 decreasing contrast levels. 228

Central Visual Field (CVF): CVF will be examined using the Amsler Chart. CVF is within 10 229 degrees radius from fixation and provides information on central vision function of the 230 participants. 231

Visual Disability Index (VDI): Using the Visual Disability Ouestionnaire (VDO), the VDI of the 232 participants will be assessed to quantify the effects of visual impairment on an individual's 233 capacity to execute daily activities. 234

Adherence: Based on a similar clinical trial (35), adherence to the physical activity 235 intervention will be defined and assessed as having done MVPA with the physical activity 236 237 tracker on for more than 75% of the intervention period and having read more than 50% of program content. 238

Incidents: Incidents will be defined as any adverse, uncomfortable, or unexpected events that
will jeopardize the ability and willingness of the participant to continue the clinical trial. This
assessment will be case dependent, ranging from telephonic evaluation to clinical evaluation
at CERL.

243 Intervention

According to the key guidelines, adults with chronic conditions or disabilities, who are able, 244 should do at least 150 minutes (2 hours and 30 minutes) to 300 minutes (5 hours) a week of 245 moderate-intensity physical activity, or 75 minutes (1 hour and 15 minutes) to 150 minutes 246 (2 hours and 30 minutes) a week of vigorous-intensity aerobic physical activity, or an 247 equivalent combination of moderate- and vigorous-intensity aerobic activity (36,37). The 248 comparison is that 1 minute of vigorous-intensity activity is equivalent to 2 minutes of 249 moderate-intensity activity. That is, the lower limit of vigorous-intensity physical activity 250 (6.0 METs) is twice the lower limit of moderate-intensity activity (3.0 METs). Therefore, 75 251 minutes of vigorous-intensity activity a week is roughly equivalent to 150 minutes of 252 moderate-intensity activity a week. 253

This is the basis for the development of the tailored physical activity regimen for each of the participants. The main moderate-intensity physical activity adopted for this study is brisk walking while that of vigorous-intensity physical activity is running. The design and implementation mirrored a similar physical activity study that assessed the impact of physical activity on abnormal glucose tolerance and visual outcomes (22). The intervention period (macrocycle) was divided into three mesocycles (four weeks each), with fixed increments with each subsequent mesocycle. For participants with T2DM, physical activity

should not be performed after taking oral hypoglycemic medication when they have noteaten.

263 Intervention group

The participants in the experimental group will undergo moderate-intensity physical 264 activity (150 minutes and above) or vigorous-intensity physical activity (75 minutes and 265 266 above), or combine the two in an equivalent way. This will depend on the age, gender, and daily activity of the participants. Subsequently, the amount of time for physical activity will 267 be increased by 75 minutes for moderate-intensity physical activity and 37.5 minutes for 268 vigorous-intensity physical activity for every four weeks during the intervention phase. The 269 physical activity will be structured, planned, individualized, and tracked during the period. 270 The activity can be performed at home, work, or at fitness facilities. There will be no more 271 272 than two consecutive days without undertaking the exercise.

The amount of time of physical activity will be self-tracked using the accelerometer and GPS sensors of the participants' smartphones. Mobile phone fitness and health applications will be used to document the patient's physical activity history. The Apple Health App will be used by participants who use IOS run mobile phones while the Google Fit App will be used by android phones users (in the cases where the brands of the android mobile phone does not have in-built fitness and health applications).

279 **Control group**

Participants in the control group will receive health education, including materials focusing on the importance of regular physical activity for overall health and well-being. The education will cover general recommendations for physical activity, potential benefits, and strategies for incorporating movement into daily life. Unlike the intervention group, there will be no prescribed duration, intensity, or frequency of engaging in physical activity. The
goal is to promote a general understanding of the benefits of physical activity without
providing a specific, planned activity regimen. As opposed to the robust tracking system set
up for the physical activities of the experimental group, the control group participants will
be asked to keep a simple log or diary of their physical activities.

Outcome Measures

290 Primary outcome: Visual outcomes

Adherence to a physical activity intervention would significantly improve visual outcomes 291 in an African population with AGT. This outcome presupposes a difference in visual 292 293 outcomes before and after the physical activity regimen has been completed by the participants. The visual outcomes being assessed in this trial will be visual acuity, contrast 294 295 sensitivity, and central visual field of the participants, before and after the introduction of the physical activity intervention. Visual acuity will be assessed using the Early Treatment 296 297 Diabetic Retinopathy Study (ETDRS) chart, contrast sensitivity will be assessed using the Pelli-Robson contrast sensitivity chart, and the central visual field (CVF) will be assessed 298 299 using the Amsler Chart.

300 Secondary outcomes: Glycemic level, Visual Disability Index, Feasibility

Glycemic level: Adherence to a physical activity intervention significantly reduces glycemic
levels in an African population with AGT. This outcome presupposes a difference in glycemic
levels before and after the physical activity regimen has been completed by the participants.
Glycemic levels in this trial will be assessed in three ways: Oral Glucose Tolerance Test
(OGTT), Glycated Hemoglobin (HbA1c), and Fasting Blood Glucose (FBG).

Visual Disability Index (VDI): The visual disability index involves a quantification of the effects of visual impairment on an individual's capacity to execute daily activities. It offers a comprehensive evaluation of the effects of ocular conditions on the general functioning of a person. Visual Disability Index (VDI) will be assessed using the Visual Disability Questionnaire (VDQ) adapted from Shrestha and Kaiti (2014) who used the inventory to study diabetic patients.

312 Feasibilty

Feasibility will be assessed by the number of people who are recruited for the trial and how well they adhere to the requirements of the trial. In addition, occurrences (positive or negative) will be assessed as well (38,39). This will be documented along with the clinical outcomes.

The clinical outcomes (FPG, HbA1c, OGTT, VA, CS, CVF) will be assessed at pre-intervention, after each mesocycle and post intervention. VDI will be measured only at pre-intervention and post-intervention. Concerning the feasibility outcome measures, data on incidence and adherence will be collected weekly, with recruitment already assessed at the preintervention stage.

322 Sample size

A total of 50 participants are expected to be recruited for this study. There will be 20 participants in each group. An additional 10 will be recruited to cater for attrition or participant dropout as recommended for RCT pilot studies (40,41).

326 **Data management**

A comprehensive database will be created and used to monitor the progress of each participant, including all assessments. All collected data will be strictly recorded and stored on a password-protected computer, accessible only to the research team, but kept with the principal investigator. An independent researcher will oversee the data collection process and ensures its safety. The analysis of the data will begin when the complete data for each assessment has been collected at all stages of the trial.

333 Statistical analysis

334 SPSS software version 27.0 (SPSS Inc, Chicago, IL) will be used to manage and analyse the 335 data. The normality of the data will be tested using the Shapiro-Wilk test. The significance 336 level for all the statistical tests will be 0.05. Descriptive statistics will be done to provide an 337 overview of the data. This would include frequencies for categorical variables, measures of 338 central tendency and spread for continuous variables.

The difference in the primary outcome (visual outcomes improving after the physical activity regimen) will be analyzed using the mixed-design Analysis of Variance (ANOVA), with a within-subjects factor (pretest and posttest) and a between- subject factor (experimental and control) at p < 0.05. This is similar to a previous experimental study carried out among patients with diabetic retinopathy (22).

The secondary outcome or difference in glycemic levels after the physical activity intervention will be analyzed using a paired t-test to compare the changes in the visual disability index within each group from baseline to post-intervention. An independentsamples t-test will be used to assess the difference in glycemic levels between the

intervention and control groups at post-intervention. This is similar to a study which
investigated the effect of a physical activity promotion program on the adherence to physical
activity among people living with type 2 diabetes (42).

The other secondary outcome of visual disability index, reducing after the physical activity intervention, will be assessed with within-group comparisons using a paired t-test to compare the changes in the visual disability index within each group, from baseline to postintervention. Also, between-group comparisons will be made using independent-samples ttest to assess the changes in VDI between the experimental group and control group at postintervention, with p-value less than 0.05 considered significant.

357 Ethics

This study will adhere to the tenets of the Declaration of Helsinki on research involving human subjects (43). The protocol has also been approved by the UCCIRB (UCCIRB/EXT/2022/27). In addition, this research is registered with the Pan African Clinical Trails Registry - PACTR202401462338744.

Furthermore, the dataset from this study will only be accessible to the researcher responsible for analyzing the data. To maintain confidentiality and privacy of the participants, the data will be ciphered by assigning codes to conceal any details that might identify a participant.

366 **Discussion**

Evidence suggests that before visible fundus changes appear in patients with abnormal glucose tolerance, there is some substantial inner retinal dysfunction caused by the elevated glycemic levels (17). This is characterized by morphological changes in the Retinal Ganglion

370 Cell (RGC) and inner retinal layers of the patients (44). Accordingly, the condition could be
371 caused by chronic exposure to high glucose levels that induces oxidative stress and activates
372 inflammatory pathways in the retina, which in turn affects perception of vision and proper
373 visual functioning (17,45,46).

There is a strong scientific evidence to suggest that non-pharmacological lifestyle changes, 374 like regular physical activity, can reduce the risk of cardiovascular diseases (CVD), type 2 375 diabetes, metabolic syndrome, obesity, and certain types of cancer (36). Regular physical 376 activity includes structured exercise in a variety of forms and it offers a net benefit for most 377 individuals living with T2DM (7,11,35,47). For instance, regular physical activity enhances 378 insulin sensitivity, increases cardiorespiratory fitness, improves glycemic control, reduces 379 the risk of cardiovascular mortality, and enhances psychosocial well-being (13). The term 380 "trained eye", akin to the phrase "trained heart" used in cardiology, highlights the positive 381 382 effects of physical activity on not only the health of the eye, but also on the eye and the visual system (48). 383

Many studies have investigated the effect of non-pharmacological interventions on selected 384 visual functions, and recorded some positive change in visual functioning (21,22). An 385 interventional study assessed the effect of a multicomponent nutritional formula on visual 386 functions among people with both short and long-term diabetes and found that the 387 intervention offered some overall protection of visual function associated with the onset and 388 progression of DR in both groups (21). However, this study was conducted at a single center 389 and did not discover any significant intergroup difference. To improve on the previous 390 391 results, another study (22) designed an individual-specific tailored physical activity intervention to improve compliance and elicit uniform results, regardless of the varying 392

glycemic levels among the participants. The study recorded decreased glycemic levels and a 393 resulting improvement in visual functioning, especially visual acuity. However, their did not 394 include people with prediabetes as the focus was on diabetic patients who are likely to be on 395 396 other interventions (22). Thus, it is important to also assess the efficacy of these interventions on both diabetic and prediabetic persons. Also, adherence in these studies was 397 self-reported by the patients, making such measurements very subjective. Therefore, it is 398 important to assess the efficacy of a physical activity regimen on visual outcomes among 399 newly diagnosed patients with AGT, and that adherence to the regimen is measured 400 objectively. 401

This trial has the element of objective tracking of the physical activity regimen. Subjective 402 tracking where patients record how much physical activity they have done poses a challenge 403 because of the case of self-desirability bias it presents (49). There is a growing emphasis on 404 self-monitoring applications that allow patients to measure and track their own physical 405 health parameters (weight, physical activity, blood pressure, blood glucose level, lung 406 407 function), and where patients' willingness to self-monitor might be associated with disease 408 controllability (50). In fact, among patients with diabetes mellitus, asthma, hypertension, rheumatism and migraine, those with diabetes mellitus have been found to be more willing 409 to self-monitor their health parameters (50). 410

At the conclusion of this trial, we expect to identify changes in visual outcomes, especially visual acuity, as was found in a recent study that tested for similar outcomes (22). Also, it is expected that there will be changes in the VDI of the participants as has been observed in a previous study (32). Generally, this trial seeks to confirm the associations that have been comprehensively described by a recent systematic review on the topic area (23).

416 **Strengths and Weaknesses**

While there will be efforts to ensure blinding, there remains a possibility of bias because the experimental group will be motivated more than the control group to be more physically active. The other limitation is that the study is based on participants following the prescribed exercise regimen to the latter. This may vary due to personal preferences, lifestyle, or challenges to exercise.

Despite these limitations, the study's strengths lie in its rigorous design, detailed outcome measures, objectives, and accurate adherence monitoring. While adhering to the ethical guidelines, this research intends to give a comprehensive analysis of the feasibility and preliminary efficacy of physical activity interventions for improving visual outcomes among people with AGT.

427 **Data availability**

438 **References**

- 1. International Diabetes Federation. IDF Diabetes Atlas. 10th editi. Brussels; 2021.
- 440 2. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, et al.
- 441 Abnormal glucose tolerance--a common risk factor in patients with acute myocardial
- infarction in comparison with population-based controls. J Intern Med. 2004
- 443 Oct;256(4):288–97.
- 444 3. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for
- 445 Abnormal Glucose Tolerance in Adolescents with Polycystic Ovary Syndrome. J Clin
- 446 Endocrinol Metab [Internet]. 2002 Mar 1;87(3):1017–23. Available from:
- 447 https://doi.org/10.1210/jcem.87.3.8305
- 448 4. Asamoah-Boaheng M, Sarfo-Kantanka O, Tuffour A, Eghan B, Mbanya J. Prevalence

449 and risk factors for diabetes mellitus among adults in Ghana: a systematic review and

450 meta-analysis. Int Health. 2019;11(2):83–92.

- 451 5. Faiq MA, Sengupta T, Nath M, Velpandian T, Saluja D, Dada R, et al. Ocular
- 452 manifestations of central insulin resistance. Neural Regen Res. 2023
- 453 May;18(5):1139–46.
- 454 6. Mansour A, Mousa M, Abdelmannan D, Tay G, Hassoun A, Alsafar H. Microvascular

and macrovascular complications of type 2 diabetes mellitus: Exome wide

- 456 association analyses. Front Endocrinol (Lausanne) [Internet]. 2023;14:1143067.
- 457 Available from: https://www.frontiersin.org/articles/10.3389/fendo.2023.1143067
- 458 7. Bukht M, Ahmed K, Hossain S, Masud P, Sultana S, Khanam R. Association between
- 459 physical activity and diabetic complications among Bangladeshi type 2 diabetic
- 460 patients. Diabetol Metab Syndr. 2019;13(1):806–9.

461	8.	Bourne RRA, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of
462		vision loss worldwide, 1990-2010: A systematic analysis. Lancet Glob Heal. 2013
463		Dec;1(6):e339-49.

- 464 9. Issaka A, Paradies Y, Stevenson C. Modifiable and emerging risk factors for type 2
- diabetes in Africa: a systematic review and meta-analysis protocol. Syst Rev.
- 466 2018;7:139.
- 467 10. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al.
- 468 Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the
- American Diabetes Association (ADA) and the European Association for the Study of
- 470 Diabetes (EASD). Diabetologia. 2022;65(12):1925–66.
- 471 11. Denche-Zamorano Á, Mendoza-Muñoz DM, Barrios-Fernandez S, Perez-Corraliza C,

472 Franco-García JM, Carlos-Vivas J, et al. Physical activity reduces the risk of developing
473 diabetes and diabetes medication use. Healthcare. 2022 Dec;10(12):2479.

- 474 12. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et
- al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with
 impaired glucose tolerance. N Engl J Med. 2001 May;344(18):1343–50.
- 477 13. Carbone S, Del Buono MG, Ozemek C, Lavie CJ. Obesity, risk of diabetes and role of
- 478 physical activity, exercise training and cardiorespiratory fitness. Prog Cardiovasc
- 479 Dis. 2019;62(4):327–33.

6.

- 480 14. Bao YK, Yan Y, Gordon M, McGill JB, Kass M, Rajagopal R. Visual field loss in patients
- 481 with diabetes in the absence of clinically-detectable vascular retinopathy in a
- 482 nationally representative survey. Invest Ophthalmol Vis Sci. 2019 Nov;60(14):4711–
- 483

484	15.	Gualtieri M, Bandeira M, Hamer RD, Damico FM, Moura ALA, Ventura DF. Contrast
485		sensitivity mediated by inferred magno- and parvocellular pathways in type 2
486		diabetics with and without nonproliferative retinopathy. Invest Ophthalmol Vis Sci.
487		2011 Feb;52(2):1151–5.
488	16.	Mirković J, Risimić D. Contrast sensitivity in patients with diabetes mellitus. Med
489		Podml. 2018;69(4):35–9.
490	17.	Nagai N, Mushiga Y, Ozawa Y. Evaluating fine changes in visual function of diabetic
491		eyes using spatial-sweep steady-state pattern electroretinography. Sci Rep
492		[Internet]. 2023;13(1):13686. Available from: https://doi.org/10.1038/s41598-023-
493		40686-5
494	18.	Pinilla I, Ferreras A, Idoipe M, Sanchez-Cano AI, Perez-Garcia D, Herrera LX, et al.
495		Changes in frequency-doubling perimetry in patients with type I diabetes prior to
496		retinopathy. Biomed Res Int. 2013;2013:341269.
497	19.	Siersma V, Køster-Rasmussen R, Bruun C, Olivarius N de F, Brunes A. Visual
498		impairment and mortality in patients with type 2 diabetes. BMJ open diabetes Res
499		care. 2019;7(1):e000638.
500	20.	Stavrou EP, Wood JM. Letter contrast sensitivity changes in early diabetic
501		retinopathy. Clin Exp Optom. 2003 May;86(3):152–6.
502	21.	Chous AP, Richer SP, Gerson JD, Kowluru RA. The Diabetes Visual Function
503		Supplement Study (DiVFuSS). Br J Ophthalmol [Internet]. 2016 Feb 1;100(2):227–34.
504		Available from: http://bjo.bmj.com/content/100/2/227.abstract
505	22.	Pardhan S, Upadhyaya T, Smith L, Sharma T, Tuladhar S, Adhikari B, et al. Individual
506		patient-centered target-driven intervention to improve clinical outcomes of diabetes,

- health literacy, and self-care practices in Nepal: A randomized controlled trial. Front
 Endocrinol (Lausanne). 2023;14:1076253.
- 509 23. AlQabandi Y, Nandula SA, Boddepalli CS, Gutlapalli SD, Lavu VK, Abdelwahab
- 510 Mohamed Abdelwahab R, et al. Physical activity status and diabetic retinopathy: A
- 511 review. Cureus. 2022 Aug;14(8):e28238.
- 512 24. Sathish T, Oldenburg B, Thankappan KR, Absetz P, Shaw JE, Tapp RJ, et al. Cost-
- effectiveness of a lifestyle intervention in high-risk individuals for diabetes in a low-
- and middle-income setting: Trial-based analysis of the Kerala Diabetes Prevention
- 515 Program. BMC Med. 2020 Sep;18(1):251.
- 516 25. Singh K, Chandrasekaran AM, Bhaumik S, Chattopadhyay K, Gamage AU, Silva P De, et
- al. Cost-effectiveness of interventions to control cardiovascular diseases and diabetes
- 518 mellitus in South Asia: A systematic review. BMJ Open. 2018;8(4):e017809.
- 519 26. Edlind M, Mitra N, Grande D, Barg FK, Carter T, Turr L, et al. Why effective
- 520 interventions do not work for all patients: exploring variation in response to a
- 521 chronic disease management intervention. Med Care. 2018 Aug;56(8):719–26.
- 522 27. Skoglund G, Nilsson BB, Olsen CF, Bergland A, Hilde G. Facilitators and barriers for
- 523 lifestyle change in people with prediabetes: a meta-synthesis of qualitative studies.
- 524 BMC Public Health [Internet]. 2022;22(1):553. Available from:
- 525 https://doi.org/10.1186/s12889-022-12885-8
- 526 28. Ma JK, Floegel TA, Li LC, Leese J, De Vera MA, Beauchamp MR, et al. Tailored physical
 527 activity behavior change interventions: challenges and opportunities. Transl Behav
 528 Med. 2021 Dec;11(12):2174–81.
- 529 29. Collado-Mateo D, Lavín-Pérez AM, Peñacoba C, Del Coso J, Leyton-Román M, Luque-

530 (Lasado A	et al. Key	/ factors	associated	with a	dherence to	ph o	vsical	exercise ir	n patients

- 531 with chronic diseases and older adults: An umbrella review. Int J Environ Res Public
- 532 Health. 2021 Feb;18(4).
- 533 30. IAPB, IDF. Diabetic Retinopathy: A Call for Global Action. 2024.
- 534 31. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.
- 535 SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann
- 536 Intern Med. 2013 Feb;158(3):200–7.
- 537 32. Shrestha GS, Kaiti R. Visual functions and disability in diabetic retinopathy patients. J

538 Optom [Internet]. 2014;7(1):37–43. Available from:

- 539 https://www.sciencedirect.com/science/article/pii/S188842961300023X
- 540 33. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al.
- 541 Classification and diagnosis of diabetes: Standards of care in diabetes—2023.
- 542 Diabetes Care [Internet]. 2022 Dec 12;46(Supplement_1):S19–40. Available from:
- 543 https://doi.org/10.2337/dc23-S002
- 34. Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. In Treasure Island
 (FL); 2024.
- 546 35. Kooiman TJM, de Groot M, Hoogenberg K, Krijnen WP, van der Schans CP, Kooy A.

547 Self-tracking of physical activity in people with type 2 diabetes: A randomized

- controlled trial. Comput Inform Nurs. 2018 Jul;36(7):340–9.
- 54936.Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The
- 550 physical activity guidelines for Americans. JAMA. 2018 Nov;320(19):2020–8.
- 551 37. DiPietro L, Buchner DM, Marquez DX, Pate RR, Pescatello LS, Whitt-Glover MC. New
- scientific basis for the 2018 U.S. Physical Activity Guidelines. J Sport Heal Sci. 2019

553	May;8(3)):197–200.
-----	----------	------------

- 38. Morris NS, Rosenbloom DA. CE: Defining and understanding pilot and other
 feasibility studies. Am J Nurs. 2017 Mar;117(3):38–45.
- 556 39. Resnick B. The definition, purpose and value of pilot research. Geriatr Nurs.

557 2015;36(2):S1–2.

40. Kieser M, Wassmer G. On the use of the upper confidence limit for the variance from

a pilot sample for sample size determination. Biometrical J [Internet]. 1996 Jan

560 1;38(8):941–9. Available from: https://doi.org/10.1002/bimj.4710380806

41. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a

pilot randomised trial to minimise the overall trial sample size for the external pilot

and main trial for a continuous outcome variable. Stat Methods Med Res. 2016

564 Jun;25(3):1057–73.

- 565 42. Eshete A, Mohammed S, Shine S, Eshetie Y, Assefa Y, Tadesse N. Effect of physical
- activity promotion program on adherence to physical exercise among patients with
- 567 type II diabetes in North Shoa Zone Amhara region: a quasi-experimental study. BMC

568 Public Health [Internet]. 2023;23(1):709. Available from:

569 https://doi.org/10.1186/s12889-023-15642-7

43. World Medical Association. World Medical Association Declaration of Helsinki:

- 571 Ethical principles for medical research involving human subjects. JAMA. 2013
- 572 Nov;310(20):2191-4.

44. Amato R, Catalani E, Dal Monte M, Cammalleri M, Cervia D, Casini G. Morpho-

- 574 functional analysis of the early changes induced in retinal ganglion cells by the onset
- 575 of diabetic retinopathy: The effects of a neuroprotective strategy. Pharmacol Res

576 [Internet]. 2022;185:106516. Available from:

577 https://www.sciencedirect.com/science/article/pii/S1043661822004625

- 578 45. Park HYL, Kim IT, Park CK. Early diabetic changes in the nerve fibre layer at the
- 579 macula detected by spectral domain optical coherence tomography. Br J Ophthalmol.
- 580 2011 Sep;95(9):1223-8.
- 581 46. Spaide RF. Measurable aspects of the retinal neurovascular unit in diabetes,
- glaucoma, and controls. Am J Ophthalmol. 2019 Nov;207:395–409.
- 583 47. Amin M, Kerr D, Atiase Y, Yakub Y, Driscoll A. Understanding physical activity
- 584 behavior in Ghanaian adults with type 2 diabetes: A qualitative descriptive study. J
- 585 Funct Morphol Kinesiol. 2023;8(3):127.
- 586 48. Szalai I, Pálya F, Csorba A, Tóth M, Somfai G. The effect of physical exercise on the
 587 retina and choroid. Klin Monbl Augenheilkd. 2020;237(4):446–9.
- 49. Howitt C, Brage S, Hambleton IR, Westgate K, Samuels TA, Rose AMC, et al. A cross-
- sectional study of physical activity and sedentary behaviours in a Caribbean
- 590 population: combining objective and questionnaire data to guide future
- interventions. BMC Public Health [Internet]. 2016;16(1):1036. Available from:
- 592 https://doi.org/10.1186/s12889-016-3689-2
- 593 50. Huygens MWJ, Swinkels ICS, de Jong JD. Self-monitoring of health data by patients
- 594 with a chronic disease: does disease controllability matter? BMC Fam Pract.
- 595 2017;18:40.


596

598 Supporting Information

- 599 Supporting Information file S1.
- 600 Supporting Information file S2.

	Enrollment	Allocation	Baseline	Intervent	Post-Intervention	Close-Out		
Timepoint	0	0	0	W1-W4	W5-W8	W9-W12		
				(Mesocycle 1)	(Mesocycle II)	(Mesocycle III)		
Enrollment:	X							
Eligibility screen	X							
Informed consent	X							
Allocation		X						
Interventions:								
Intervention A (Physical Activity Intervention)				х	x	х		
Intervention B (Control)				х	X	Х		
Assessments:							X	
Age			X					
Sex			X					
Body mass index			X				X	
Physical Activity (Yes/No)			Х	Х	X	Х	x	
Physical Activity (minutes/week)			х	х	x	х	x	
Fasting Plasma Glucose (FPG)			х				x	
Glycated Hemoglobin (HbA1c)			X				X	
Oral Glucose Tolerance Test (OGTT)			x				x	
Visual Acuity			X				X	
Visual Field			X				X	
Contrast Sensitivity			X				X	
Visual Disability Index			Х				X	
Adherence			X	Х	X	Х	X	
Incidents			X	Х	X	Х	X	
Statistical Analysis								X

Fig 1. SPIRIT schedule of enrolment, interventions, and assessme



Analysis

Analyzed (n=) Excluded from analysis (with reasons) (n=) Lost to follow-up (n=)

Fig 2. Flow chart of the RCT process for the participants in the st